Abstract #0192

Amide proton transfer-weighted MRI signal as a surrogate biomarker to assess MGMT promoter methylation status in glioblastoma

Shanshan Jiang^1,2, Xianlong Wang², Yu Wang³, Hao Yu², Tianyu Zou², Yongxing Du², Charles Eberhart⁴, Maria Adelita Vizcaino Villalobos⁴, Yi Zhang¹, Hye-Young Heo¹, Peter Van Zijl¹, Zhibo Wen², and Jinyuan Zhou¹

¹Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, United States, ²Department of Radiology, Southern Medical University, Zhujiang Hospital, Guangzhou, People's Republic of China, ³Department of Pathology, Southern Medical University, Zhujiang Hospital, Guangzhou, People's Republic of China, ⁴Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States

We explored the feasibility of using the APTW signal intensity as a surrogate biomarker to identify the methylation status of MGMT promoter in glioblastoma (GBM). Eighteen patients with newly diagnosed GBM were recruited and scanned. Results showed that the APTW signal intensities were significantly higher in the unmethylated MGMT promoter group than in the methylated MGMT promoter group. The area under the ROC curve (AUC) for APTW to differentiate these two GBM groups was 0.857. Preoperative APTW imaging may assist in predicting the MGMT promoter methylation status in patients with GBM.

This abstract and the presentation materials are available to members only; a login is required.

Join Here